Insider Shareholders with Direct Ownership of Cytom X Therapeutics, Inc. (CTMX)
This section provides a comprehensive overview of the insiders with direct ownership of Cytom X Therapeutics, Inc. (CTMX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
CytomX Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 1,310,317 | 188,805 | 1,032,851 $805,623 | 24 |
Feb 04, 2025
Added 15.88%
|
|
|
Marcia Belvin
SVP, Chief Scientific Officer |
207,500 | 25,172 | 263,148 $205,255 | 10 |
Feb 04, 2025
Added 17.93%
|
|
Christopher Ogden
Chief Financial Officer |
197,750 | 7,461 | 209,577 $163,470 | 10 |
Feb 04, 2025
Added 21.53%
|
|
Yu Waye Chu
Chief Medical Officer |
139,750 | 0 | 139,750 $109,005 | 2 |
Feb 04, 2025
Added 29.15%
|
|
Lloyd A Rowland
General Counsel |
125,000 | 26,651 | 130,797 $102,021 | 13 |
Aug 20, 2024
Reduced 3.1%
|
|
Jeffrey B Landau
Chief Business Officer |
115,000 | 24,622 | 119,056 $92,863 | 12 |
Aug 20, 2024
Reduced 3.39%
|
|
Amy C. Peterson
EVP, Chief Development Officer |
66,421 | 11,720 | 58,433 $45,577 | 6 |
Mar 16, 2023
Reduced 6.79%
|
|
Carlos Campoy
Chief Financial Officer |
43,921 | 5,697 | 38,224 $29,814 | 6 |
Mar 16, 2023
Reduced 4.37%
|
|
Alison L. Hannah
Chief Medical Officer |
37,500 | 5,602 | 31,898 $24,880 | 3 |
Jul 20, 2022
Reduced 14.94%
|
| 5,000 | 0 | 5,142 $4,010 | 1 |
Mar 29, 2023
Added 49.3%
|